Tags

Type your tag names separated by a space and hit enter

Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial.

Abstract

BACKGROUND

Health-related quality of life (HRQoL) has been rarely evaluated as a primary endpoint in the assessment of the effect of probiotics on the irritable bowel syndrome (IBS).

AIM

To study the effects of fermented milk containing Bifidobacterium animalis DN-173 010 and yoghurt strains on the IBS in a multicentre, double-blind, controlled trial.

METHODS

A total of 274 primary care adults with constipation-predominant IBS (Rome II) were randomized to consume for 6 weeks either the test fermented milk or a heat-treated yoghurt (control). HRQoL and digestive symptoms were assessed after 3 and 6 weeks on an intention-to-treat population of 267 subjects.

RESULTS

The HRQoL discomfort score, the primary endpoint, improved (P < 0.001) in both groups at weeks 3 and 6. The responder rate for the HRQoL discomfort score was higher (65.2 vs. 47.7%, P < 0.005), as was the decrease in bloating score [0.56 +/- (s.d.)1.01 vs. 0.31 +/- 0.87, P = 0.03], at week 3 in the test vs. the control group. In those subjects with <3 stools/week, stool frequency increased (P < 0.001) over 6 weeks in the test vs. control group.

CONCLUSIONS

This study suggests a beneficial effect of a probiotic food on discomfort HRQoL score and bloating in constipation-predominant IBS, and on stool frequency in subjects with <3 stools/week.

Links

  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Danone Research, Route Départementale 128, 91767 Palaiseau, France. denis.guyonnet@danone.com

    , , , , ,

    Source

    Alimentary pharmacology & therapeutics 26:3 2007 Aug 01 pg 475-86

    MeSH

    Adolescent
    Adult
    Aged
    Bifidobacteriales Infections
    Bifidobacterium
    Double-Blind Method
    Female
    Humans
    Irritable Bowel Syndrome
    Male
    Middle Aged
    Primary Health Care
    Probiotics
    Quality of Life
    Treatment Outcome
    Yogurt

    Pub Type(s)

    Journal Article
    Multicenter Study
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    17635382

    Citation

    Guyonnet, D, et al. "Effect of a Fermented Milk Containing Bifidobacterium Animalis DN-173 010 On the Health-related Quality of Life and Symptoms in Irritable Bowel Syndrome in Adults in Primary Care: a Multicentre, Randomized, Double-blind, Controlled Trial." Alimentary Pharmacology & Therapeutics, vol. 26, no. 3, 2007, pp. 475-86.
    Guyonnet D, Chassany O, Ducrotte P, et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther. 2007;26(3):475-86.
    Guyonnet, D., Chassany, O., Ducrotte, P., Picard, C., Mouret, M., Mercier, C. H., & Matuchansky, C. (2007). Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Alimentary Pharmacology & Therapeutics, 26(3), pp. 475-86.
    Guyonnet D, et al. Effect of a Fermented Milk Containing Bifidobacterium Animalis DN-173 010 On the Health-related Quality of Life and Symptoms in Irritable Bowel Syndrome in Adults in Primary Care: a Multicentre, Randomized, Double-blind, Controlled Trial. Aliment Pharmacol Ther. 2007 Aug 1;26(3):475-86. PubMed PMID: 17635382.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. AU - Guyonnet,D, AU - Chassany,O, AU - Ducrotte,P, AU - Picard,C, AU - Mouret,M, AU - Mercier,C-H, AU - Matuchansky,C, PY - 2007/7/20/pubmed PY - 2007/12/15/medline PY - 2007/7/20/entrez SP - 475 EP - 86 JF - Alimentary pharmacology & therapeutics JO - Aliment. Pharmacol. Ther. VL - 26 IS - 3 N2 - BACKGROUND: Health-related quality of life (HRQoL) has been rarely evaluated as a primary endpoint in the assessment of the effect of probiotics on the irritable bowel syndrome (IBS). AIM: To study the effects of fermented milk containing Bifidobacterium animalis DN-173 010 and yoghurt strains on the IBS in a multicentre, double-blind, controlled trial. METHODS: A total of 274 primary care adults with constipation-predominant IBS (Rome II) were randomized to consume for 6 weeks either the test fermented milk or a heat-treated yoghurt (control). HRQoL and digestive symptoms were assessed after 3 and 6 weeks on an intention-to-treat population of 267 subjects. RESULTS: The HRQoL discomfort score, the primary endpoint, improved (P < 0.001) in both groups at weeks 3 and 6. The responder rate for the HRQoL discomfort score was higher (65.2 vs. 47.7%, P < 0.005), as was the decrease in bloating score [0.56 +/- (s.d.)1.01 vs. 0.31 +/- 0.87, P = 0.03], at week 3 in the test vs. the control group. In those subjects with <3 stools/week, stool frequency increased (P < 0.001) over 6 weeks in the test vs. control group. CONCLUSIONS: This study suggests a beneficial effect of a probiotic food on discomfort HRQoL score and bloating in constipation-predominant IBS, and on stool frequency in subjects with <3 stools/week. SN - 0269-2813 UR - https://www.unboundmedicine.com/medline/citation/17635382/full_citation L2 - https://doi.org/10.1111/j.1365-2036.2007.03362.x DB - PRIME DP - Unbound Medicine ER -